You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 11 - 20 of 3622 results
  1. Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenza

    SBC: TFF PHARMACEUTICALS, INC.            Topic: NIAID

    PROJECT SUMMARY TFF Pharmaceuticals (TFFP) is developing a shelf-stable thin-film freeze (TFF) dry powder universal flu vaccine. Commercialization of this product would provide the first vaccine that is at least 75% effective against symptomatic influenza virus infection, with the added benefit of easy delivery and storage at room temperature to facilitate broad, cost-effective distribution. With ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. High-throughput functional analysis and clinical relevance of all possible variants of a gene

    SBC: HELIGENICS, INC.            Topic: NHGRI

    Modern pharmaceuticals have greatly improved the quality of life for many patients suffering a variety of illnesses. Unfortunately, among the 17 most commonly prescribed drugs, only 6 are highly effective for most patients, 5 have a modest effect, and 6 show little clinical effect. Worse still, unwanted illness and death from treatment of patients with the incorrect drug or dosage causes over 275, ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Novel approaches for the treatment of autoimmune disease

    SBC: ASTERO ERADO INC            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT The overall goal of this project is to develop a novel therapeutic for the treatment of immune- mediated thrombotic thrombocytopenic purpura (iTTP). iTTP is an acute, life-threatening disease that without treatment, leads to a rt90% mortality rate. It is caused by deficiency of a disintegrin and metalloprotease thrombospondin type 1 motif, member 13 (ADAMTS13), which is a ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation

    SBC: STEMBIOSYS, INC.            Topic: 200

    Project Summary/Abstract Compared to daily multiple insulin injections, pancreatic islet transplantation for type 1 diabetes (loss of β-cells) or the latter stages of type 2 diabetes (β-cells fail to produce sufficient insulin) provides a near physiologic regulation of normal blood glucose levels and significantly improves quality of life by minimizing severe hypoglycemia and diabetic complicati ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities

    SBC: EPIVAX, INC.            Topic: NIAID

    ABSTRACT The identification and removal of process-related protein impurities (PRPI) from biologic products is a critical step in drug development. Despite recent improvements in the purification and processing of biologics, the presence of immunogenic PRPI continue to raise concerns about drug safety and efficacy. We propose an innovative approach for assessing immunogenicity risk of PRPI using o ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Clinical Decision Support System for Early Detection of Cognitive Decline Using Electronic Health Records and Deep Learning

    SBC: Melax Technologies, Inc            Topic: NIA

    Project Summary The prevalence of Alzheimer’s disease (AD) and related dementia (AD/ADRD) is expected to nearly triple to a staggering 13 million affected Americans and the total costs of care are projected to increase five-fold to 1.1 trillion dollars by the year 2050. Early detection of precursor stages of AD/ADRD becomes extremely important, as it can introduce treatment or intervention earli ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Quantitative Normalization of Spatial Metabolomics for Molecular Signatures of Tissue Heterogeneity

    SBC: SYGNAMAP INC            Topic: 400

    PROJECT SUMMARY The molecular and biochemical basis of tissue heterogeneity in normal and disease states can be addressed with spatial omic analysis. Advances in spatial metabolomic analysis of tissue biopsies using MALDI-MSI could enable the identification of numerous biochemical pathways as signatures of specific histopathology features. However, to extract the most robust disease- relevant biom ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. The Development of CSD peptides for the therapeutic treatment of post-acute sequelae of COVID-19 (PACS)

    SBC: LUNG THERAPEUTICS INC            Topic: NHLBI

    Abstract Acute respiratory distress syndrome (ARDS) from SARS-CoV-2 infection activates many lung remodeling pathways observed in Idiopathic Pulmonary Fibrosis (IPF) and reports indicate that symptoms persist for 2 to 12 months or longer in approximately 33% of hospitalized patients. To address this emerging health concern, this proposal aims to 1) develop a translational model for post-acute COVI ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Image-guided Surgical Detection of Metastatic Disease to the Peritoneum

    SBC: Onconano Medicine, Inc.            Topic: 102

    Summary (application predicated on NIH NCI Phase II 5R44CA217528-03): Surgical resection is a common front-line treatment for cancer that relies heavily on the surgeon’s ability to identify disease preoperatively and intraoperatively. While typical standard of care (SOC) preoperative diagnostics such as PET, CT, ultrasound, and MRI afford the surgeon critically important tools, they suffer from ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. SOMNAR: A platform to localize airway obstruction in sleep apnea

    SBC: BAIRITONE HEALTH INC.            Topic: NHLBI

    Abstract - An estimated 24 million undiagnosed or untreated people with OSA (obstructive sleep apnea) contribute to a $150B economic burden in the US. Most people with OSA are prescribed continuous positive airway pressure (CPAP) as a first line treatment, but CPAP has a 50% failure rate. Highly effective treatments that target the anatomic causes of OSA are available but are only effective when t ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government